QNRX News & Events

Quoin Pharmaceuticals announced that it has completed the establishment of a wholly-owned subsidiary in Japan as part of its strategy to directly commercialize QRX003 for the treatment of Netherton Syndrome, if approved. The formation follows the recent grant of Orphan Drug Designation to QRX003 by Japan's Ministry of Health, Labour and Welfare, MHLW, and supports Quoin's long-term commercial plans in one of its three core markets.

Quoin Pharmaceuticals announced a positive clinical update from its ongoing pediatric Netherton Syndrome Compassionate Use program evaluating its drug candidate, QRX003. Four of the six enrolled patients, all under 10 years of age, were classified as "Improved" or "Significantly Improved" from their baseline assessments across key clinical endpoints. No treatment-related adverse events have been reported. Quoin plans to enroll additional pediatric patients in June and September and expects to release comprehensive clinical data from this program and its ongoing Phase 2 studies in the coming months. "With a remarkable 4 out of 6 children in the program responding positively and showing clear signs of improvement across key clinical endpoints when treated with QRX003, we are encouraged and remain optimistic about the potential for the product to become the first approved treatment for this disease," said Dr. Michael Myers, CEO.

Quoin Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare, or MHLW, has granted Orphan Drug Designation to QRX003 for the treatment of Netherton Syndrome, a rare and severe genetic skin disorder for which there are currently no approved treatments.